Sign in or register to see full information and data.

Studies / CAVD 579

Overview

Study information

Network:CAVD
Grant Affiliation:Third party request
Strategy:Prophylactic neutralizing Ab
Study Type:Phase I
Species:Human
Stage:Assays Completed
Study Start Date:2013-07-24
Study Made Public:2016-10-25

Title

Immunogenicity of heterologous boost immunizations with MVA-CMDR, a modified vaccinia Ankara HIV-1 vaccine expressing Env gp 150/gag/pol, in HIV-uninfected volunteers previously immunized with DCVax-001 plus poly-ICLC

Description

CAVD 579 (SSC-0803 or TP 22) is a phase I study to evaluate the safety and immunogenicity of heterologous boost immunizations with MVA-CMDR in HIV-uninfected healthy participants previously immunized with the monoclonal antibody, DCVax-001, plus HiltonolĀ® in CAVD 264 (DC Vax).

Products

Saline (non-specific) DC-VAX Poly ICLC 2004 MVA-CMDR

Integrated data

BAMA, ICS

Non-integrated data

No non-integrated data is available for this study.